On May 22, Click Therapeutics, Inc. announced that it had acquired assets of Better Therapeutics, Inc.
Better Therapeutics is a first-in-class prescription digital therapeutic developed to deliver behavioral therapy to patients. Better went public through a merger with SPAC Mountain Crest Acquisition Corp. during the fall of 2021.
The Better Therapeutics assets being acquired include the first FDA-authorized prescription digital therapeutic for type 2 diabetes, AspyreRx, as well as development candidates BT-002, BT-003 and BT-004 for hypertension, hyperlipidemia and metabolic dysfunction-associated steatohepatitis.
Click Therapeutics, Inc. develops, validates and commercializes software as prescription medical treatments for people with unmet medical needs. It is based in New York City and was founded in 2012.
This acquisition strengthens Click’s portfolio of digital treatments for patients by immediately advancing its pipeline in obesity, diabetes and cardiometabolic diseases, complementing existing assets in psychiatry, central nervous system and pain disorders. The financial terms were not disclosed.
According to data captured in the LevinPro HC database, this acquisition marks the 29th Behavioral Health Care transaction of 2024.
